“I feel the subsequent step is when you consider how we generate data and the way protected that’s in regulatory filings. India doesn’t have regulatory data protection,” he mentioned replying to a question.
If one appears at anywhere on the planet the place there may be vital basic drug analysis occurring from multinational corporations, there may be regulatory data protection, together with China, Narasimhan additional mentioned.
The Novartis CEO added that getting approvals for scientific trials used to be very tough in India earlier. However, with the brand new coverage, the method has been streamlined.
According to him, India has the chance to attract basic drug analysis if it continues to strengthen IP and regulatory data protection environments in the long term.
“I feel that needs to be the aspiration for India in the long run. The nationwide coverage setting needs to evolve to assist that,” he mentioned.
On Novartis’ Drug Development Centre in Hyderabad, Narasimhan mentioned at present it has over 9,000 workers, together with 3200, in drug improvement tasks.
